Meningitis caused by Neisseria Meningitidis, Hemophilus Influenzae Type B and Streptococcus Pneumoniae during 2005-2012 in Turkey A multicenter prospective surveillance study

dc.contributor.authorCeyhan, Mehmet
dc.contributor.authorGurler, Nezahat
dc.contributor.authorOzsurekci, Yasemin
dc.contributor.authorKeser, Melike
dc.contributor.authorAycan, Ahmet Emre
dc.contributor.authorGurbuz, Venhar
dc.contributor.authorCoskun, Yavuz
dc.date.accessioned2026-08-12T17:32:21Z
dc.date.issued2014
dc.departmentFırat Üniversitesi
dc.description.abstractSuccessful vaccination policies for protection from bacterial meningitis are dependent on determination of the etiology of bacterial meningitis. Cerebrospinal fluid (CSF) samples were obtained prospectively from children from 1 month to <= 18 years of age hospitalized with suspected meningitis, in order to determine the etiology of meningitis in Turkey. DNA evidence of Neisseria meningitidis (N. meningitidis), Streptococcus pneumoniae (S. pneumoniae), and Hemophilus influenzae type b (Hib) was detected using multiplex polymerase chain reaction (PCR). In total, 1452 CSF samples were evaluated and bacterial etiology was determined in 645 (44.4%) cases between 2005 and 2012; N. meningitidis was detected in 333 (51.6%), S. pneumoniae in 195 (30.2%), and Hib in 117 (18.1%) of the PCR positive samples. Of the 333 N. meningitidis positive samples 127 (38.1%) were identified as serogroup W-135, 87 (26.1%) serogroup B, 28 (8.4%) serogroup A and 3 (0.9%) serogroup Y; 88 (26.4%) were non-groupable. As vaccines against the most frequent bacterial isolates in this study are available and licensed, these results highlight the need for broad based protection against meningococcal disease in Turkey.
dc.description.sponsorshipNovartis Vaccines and Diagnostics; GlaxoSmithKline
dc.description.sponsorshipThe study was supported by Novartis Vaccines and Diagnostics (for 5 years) and by GlaxoSmithKline (for 2 years). The authors declare that they have no other conflicts of interest.
dc.identifier.doi10.4161/hv.29678
dc.identifier.endpage2712
dc.identifier.issn2164-5515
dc.identifier.issn2164-554X
dc.identifier.issue9
dc.identifier.orcid0000-0001-6488-8641
dc.identifier.orcid0000-0002-0339-0134
dc.identifier.orcid0000-0002-9777-5173
dc.identifier.orcid0009-0004-6904-9280
dc.identifier.pmid25483487
dc.identifier.scopus2-s2.0-84920173471
dc.identifier.scopusqualityQ1
dc.identifier.startpage2706
dc.identifier.urihttps://doi.org/10.4161/hv.29678
dc.identifier.urihttps://hdl.handle.net/11508/56612
dc.identifier.volume10
dc.identifier.wosWOS:000348316800043
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaylor & Francis Inc
dc.relation.ispartofHuman Vaccines & Immunotherapeutics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260511
dc.subjectMeningitis
dc.subjectTurkey
dc.subjectetiologic agents
dc.subjectN. meningitidis
dc.subjectS. pneumoniae
dc.subjectHib
dc.subjectepidemiology
dc.subjectsurveillance
dc.titleMeningitis caused by Neisseria Meningitidis, Hemophilus Influenzae Type B and Streptococcus Pneumoniae during 2005-2012 in Turkey A multicenter prospective surveillance study
dc.typeArticle

Dosyalar